Home › Research › Drug development
The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
Tayeb HO, Khallaf RA, Muayqil TA, Alkeridy WA, Alibrahim FS, Alfaify OA, Qadi N, Tarazi FI.. Neurosciences (Riyadh, Saudi Arabia), 2023-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment.
What this study adds
Evidence grade: Low
This is a narrative review. This consensus statement notes that standard Alzheimer's pharmacotherapies offer only modest transient cognitive and behavioral benefits, and that aducanumab was the first disease-modifying agent approved. It states that concerns about aducanumab's efficacy and side effects led regulatory institutions worldwide to restrict its use.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tayeb, H. O., Khallaf, R. A., Muayqil, T. A., Alkeridy, W. A., Alibrahim, F. S., Alfaify, O. A., et al. (2023). The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology. Neurosciences (Riyadh, Saudi Arabia). https://doi.org/10.17712/nsj.2023.2.20220133
Vancouver
Tayeb HO, Khallaf RA, Muayqil TA, Alkeridy WA, Alibrahim FS, Alfaify OA, et al. The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology. Neurosciences (Riyadh, Saudi Arabia). 2023. doi:10.17712/nsj.2023.2.20220133. PMID: 37045461.
BibTeX
@article{tayeb2023-37045461,
author = {Tayeb, H. O. and Khallaf, R. A. and Muayqil, T. A. and Alkeridy, W. A. and Alibrahim, F. S. and Alfaify, O. A. and Qadi, N. and Tarazi, F. I.},
title = {{The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology}},
journal = {Neurosciences (Riyadh, Saudi Arabia)},
year = {2023},
doi = {10.17712/nsj.2023.2.20220133},
pmid = {37045461},
url = {https://doi.org/10.17712/nsj.2023.2.20220133}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits.
- Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment.
- However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use.
- Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD.
Why it matters
This consensus statement notes that standard Alzheimer's pharmacotherapies offer only modest transient cognitive and behavioral benefits, and that aducanumab was the first disease-modifying agent approved. It states that concerns about aducanumab's efficacy and side effects led regulatory institutions worldwide to restrict its use.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurosciences (Riyadh, Saudi Arabia)) |
| Journal's citation record | 0 / 4 | Neurosciences: journal h-index 39 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.8 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Frank I. Tarazi: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | King Abdulaziz University: institution h-index 560 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37045461) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.17712/nsj.2023.2.20220133
- PubMed: 37045461
- Original source →
- Free full text: Neurosciences →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development from nearby years
Also in Drug development
107 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.